INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
View HTML
Toggle Summary Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
- Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) — - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers— NEW HAVEN, Conn., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,
View HTML
Toggle Summary Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement alternative pathway, today announced that the European Medicines Agency (EMA) Committee
View HTML
Toggle Summary Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
BLUE BELL, Pa. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S.
View HTML
Toggle Summary Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa. , March 27, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting
BLUE BELL, Pa. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the acceptance of two abstracts about
View HTML
Toggle Summary Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa. , April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
Nicole Vitullo Brings Public Company Investment and Leadership Expertise as the next Chair of Achillion Board of Directors NEW HAVEN, Conn. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the
View HTML
Toggle Summary Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
- 98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6 -
View HTML